The University of Texas Health Science Center at San Antonio
Who can join
Adults 18 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in EGP From Baseline to Post-oral Glucose Load.Primary· From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]
The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA.
Group
Value
95% CI
Placebo
-0.03
± 0.02
Exenatide
-0.18
± 0.02
Dapagliflozin
0.14
± 0.03
Exenatide and Dapagliflozin
-0.08
± 0.03
Adverse events — posted to ClinicalTrials.gov
Time frame: 4 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production \[EGP\] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test \[OGTT\].
Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and pregnancy test performed.
Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with 3-3H-glucose.
Visit 3: Double Tracer OGTT
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05482789 — Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
· Phase 4
· recruiting
NCT04909333 — Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
· NA
· completed
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2
· Phase 2
· recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part
· recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use
· NA
· recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
· Phase 1
· recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0
· recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial
· NA
· not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D
· Phase 1
· recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D
· Phase 3
· not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
· Phase 1, PHASE2
· not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 24 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331289.